Zeke Capital Advisors LLC purchased a new stake in Mylan (NASDAQ:MYL) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 14,617 shares of the company’s stock, valued at approximately $618,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rational Advisors LLC purchased a new stake in shares of Mylan in the fourth quarter valued at approximately $190,000. First Personal Financial Services boosted its holdings in shares of Mylan by 77.1% in the fourth quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after purchasing an additional 2,106 shares during the period. Lombard Odier Asset Management Europe Ltd purchased a new stake in shares of Mylan in the fourth quarter valued at approximately $209,000. Mycio Wealth Partners LLC purchased a new stake in shares of Mylan in the fourth quarter valued at approximately $212,000. Finally, Advisor Partners LLC purchased a new stake in shares of Mylan in the fourth quarter valued at approximately $214,000. Hedge funds and other institutional investors own 84.82% of the company’s stock.
Mylan (NASDAQ:MYL) opened at $41.73 on Friday. The stock has a market capitalization of $21,481.85, a price-to-earnings ratio of 9.15, a PEG ratio of 1.32 and a beta of 1.35. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.06. Mylan has a 12-month low of $29.39 and a 12-month high of $47.82.
Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. The business had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.29 billion. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The business’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.57 earnings per share. equities research analysts anticipate that Mylan will post 5.38 EPS for the current year.
In related news, Director Robert J. Coury sold 150,000 shares of the company’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $40.10, for a total value of $6,015,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 344,287 shares of company stock worth $14,409,960. Insiders own 0.69% of the company’s stock.
A number of analysts recently issued reports on MYL shares. Zacks Investment Research lowered Mylan from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Leerink Swann started coverage on Mylan in a report on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 price target for the company. Cantor Fitzgerald set a $41.00 price objective on shares of Mylan and gave the stock a “hold” rating in a research note on Thursday, March 1st. BidaskClub raised shares of Mylan from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 19th. Finally, TheStreet raised shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $46.62.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.